Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic

Página do item simplificado
dc.citation.issue5
dc.citation.volumev. 18
dc.contributor.authorLarenas-Linnemann, Desiree E. S.
dc.contributor.authorParisi, Claudio A. S.
dc.contributor.authorRitchie, Carla
dc.contributor.authorCardona-Villa, Ricardo
dc.contributor.authorCherrez-Ojeda, Ivan
dc.contributor.authorCherrez, Annia
dc.contributor.authorEnsina, Luis Felipe [UNIFESP]
dc.contributor.authorGarcia, Elizabeth
dc.contributor.authorMedina, Iris V.
dc.contributor.authorRodriguez-Gonzalez, Mnica
dc.contributor.authorSanchez Caraballo, Jorge Mario
dc.coveragePhiladelphia
dc.date.accessioned2020-07-20T16:30:53Z
dc.date.available2020-07-20T16:30:53Z
dc.date.issued2018
dc.description.abstractPurpose of Review Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017 February 2018. Recent Findings Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline >= 2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/ monthen
dc.description.abstracthowever, others are still not controlled with 300 mg/month. In these, 150 mg bimonthly could be tried, before up-dosing to 450 mg/month. On the long run (up to 3 years) omalizumab kept its efficacy. In many patients, dosing intervals could he augmented (6-8 weeks, some even more). After a 12-month treatment, about 20% showed long-term remission without relapse. Summary Some biomarkers are being detected. Adjusting omalizumab doses in urticaria patients could enhance efficacy (shortening dosing interval and/or augmenting dose) and save costs (after 12 months: extending dosing interval and/or reducing dose).en
dc.description.affiliationMed Sur Hosp & Clin Fdn, Res Unit, Torre 2,Cons 602,Puente Piedra 150, Mexico City 14050, DF, Mexico
dc.description.affiliationHosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
dc.description.affiliationHosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
dc.description.affiliationUniv Antioquia, IPS Univ, Grp Alergol Clin & Expt, Medellin, Colombia
dc.description.affiliationEspiritu Santo Univ UEES, Samborondon, Ecuador
dc.description.affiliationRespiralab Res Grp, Guayaquil, Ecuador
dc.description.affiliationUniv Med Ctr Rostock, Clin & Policlin Dermatol & Venereol, Rostock, Germany
dc.description.affiliationUniv Fed Sao Paulo, Hosp Sirio Libanes, Sao Paulo, Brazil
dc.description.affiliationUniv Los Andes, Fac Med, Fdn Santa Fe Bogota, Bogota, Colombia
dc.description.affiliationCtr Med Vitae, Buenos Aires, DF, Argentina
dc.description.affiliationUnifespUniv Fed Sao Paulo, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.1007/s11882-018-0787-5
dc.identifier.citationCurrent Allergy And Asthma Reports. Philadelphia, v. 18, n. 5, p. -, 2018.
dc.identifier.doi10.1007/s11882-018-0787-5
dc.identifier.issn1529-7322
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55568
dc.identifier.wosWOS:000432023000005
dc.language.isoeng
dc.publisherCurrent Medicine Group
dc.relation.ispartofCurrent Allergy And Asthma Reports
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectChronic inducible urticariaen
dc.subjectChronic spontaneous urticariaen
dc.subjectOmalizumaben
dc.subjectPregnancyen
dc.subjectAdverse eventsen
dc.subjectDosing intervalsen
dc.titleUpdate on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinicen
dc.typeinfo:eu-repo/semantics/review
Arquivos
Coleções
EPM - Artigos